September 30, 2020

Immunodiagnostic Systems Ltd.   
Mick Henderson   
RA Manager   
10 Didcot Way, Boldon Business Park Boldon, Tyne and Wear NE35 9PD United Kingdom

Re: K200475 Trade/Device Name: IDS-iSYS Ostase¬Æ BAP Regulation Number: 21 CFR 862.1050 Regulation Name: Alkaline phosphatase or isoenzymes test system Regulatory Class: Class II Product Code: CIN Dated: August 27, 2020 Received: August 31, 2020

Dear Mick Henderson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531- 542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical  
devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn   
(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Marianela Perez- Torres, Ph.D.   
Acting Deputy Director   
Division of Chemistry and Toxicology Devices   
OHT7: Office of In Vitro Diagnostics and Radiological Health   
Office of Product Evaluation and Quality   
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known) k200475

Device Name IDS-iSYS Ostase $^ \mathrm { \textregistered }$ BAP

Indications for Use (Describe)

The IDS-iSYS Ostase $^ \mathrm { \textregistered }$ BAP assay is an in vitro diagnostic device intended for the quantitative determination of boneA osteoporosis and Paget's disease.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

Turenotioatinatveo time to reviw instructions, search existig data sources,gather and maintainhe dataneeded and cplee and review the colection of information. Send comments regarding this burden estimate or anyother aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

# 510(k) SUMMARY

# 510k Number

k200475

# Introduction

According to the requirements of 21CFR807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter

Immunodiagnostic Systems Limited   
10 Didcot Way   
Boldon Business Park   
Boldon   
Tyne and Wear   
NE35 9PD   
United Kingdom

Contact Person: Mick Henderson Phone: $+ 4 4$ 191 5190660 Fax: $+ 4 4$ 191 5190760 Email: mick.henderson@idsplc.com

Secondary Contact: Alexandra Bennett Phone: $+ 4 4$ 191 5190660 Fax: $+ 4 4$ 191 5190760 Email: alexandra.bennett@idsplc.com

Date prepared: 28 September 2020

# Device Name

Proprietary names: IDS-iSYS Ostase¬Æ BAP   
Common names: As above   
Classification: 21CFR862.1050 Alkaline phosphatase or isoenzymes test system. Class II   
Product Code: CIN

# Predicate Device

The IDS-iSYS Ostase¬Æ BAP is substantially equivalent to other products in commercial distribution intended for similar use. We claim equivalency to the currently marketed Tandem-MP Ostase Immunoenzymetric Assay (k972666), commercially known as Ostase¬Æ BAP EIA.

# Device Description

The IDS-iSYS Ostase¬Æ BAP assay consists of one reagent cartridge and one set of calibrators (CAL A & CAL B).

The reagent cartridge contains multiple reagents:

MPM1 (Magnetic particles coated with streptavidin in a phosphate buffer with sodium azide as preservative);   
Ab-BIOT Monoclonal anti-BAP labelled with biotin, in buffer containing horse serum with bovine and mouse proteins and sodium azide as a preservative $( < 0 . 1 \% )$   
SUBS (p-nitrophenyl phosphate in a stabilising buffer containing preservatives).

Calibrators A and B are buffered bovine protein matrix containing human BAP with sodium azide as preservative $( < 0 . 1 \% )$ .

Indications for Use The IDS-iSYS Ostase $\textsuperscript { \textregistered }$ BAP assay is an in vitro diagnostic device intended for the quantitative determination of bone-specific alkaline phosphatase (BAP), an indicator of osteoblastic activity, in human serum on the IDS system. Results are to be used in conjunction with other clinical and laboratory data to aid the clinician in the management of postmenopausal osteoporosis and Paget‚Äôs disease.

Conditions for use: For in vitro diagnostic use only. Rx Only

Special instrument Requirements: IDS System (k091849)

# Comparison Tables

Similarities compared to the chosen (FDA cleared; marketed) predicate device (k972666)

#

<table><tr><td rowspan=1 colspan=1>AssayPerformance</td><td rowspan=1 colspan=1>Predicate DeviceTandem-MP OstaseImmunoenzymetric Assay(k972666), commerciallyknown as Ostase¬Æ BAP EIA</td><td rowspan=1 colspan=1>Candidate DeviceIDS-iSYS Ostase¬Æ BAP(k200475)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For quantitative determination ofBone Alkaline Phosphataseconcentration</td><td rowspan=1 colspan=1>For quantitative determination ofBone Alkaline Phosphataseconcentration</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Bone Alkaline Phosphatase</td><td rowspan=1 colspan=1>Bone Alkaline Phosphatase</td></tr><tr><td rowspan=1 colspan=1>SampleVolume</td><td rowspan=1 colspan=1>50 ŒºL</td><td rowspan=1 colspan=1>50 ŒºL</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Human Serum</td><td rowspan=1 colspan=1>Human Serum</td></tr><tr><td rowspan=8 colspan=1>Specificity,Interferingsubstances &amp;CrossReactivity</td><td rowspan=6 colspan=1>Interfering SubstancesAcetaminophen         20 mg/dLAlendronate               5 mg/dLAsprin                     50 mg/dLBilirubin                40 mg/dLunconjugatedCalcitonin - salmon   112 IU/dLCalcium                   20 mg/dLIbuprofen                 40 mg/dL</td><td rowspan=1 colspan=1>Interfering SubstancesAcetaminophen               Same</td></tr><tr><td rowspan=2 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Asprin                          Same</td></tr><tr><td rowspan=1 colspan=1>Bilirubin                      SameunconjugatedCalcitonin  salmon         SameCalcium                        Same</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen                       Same</td></tr><tr><td rowspan=1 colspan=1>Pamidronate             18 mg/dL</td><td rowspan=1 colspan=1>Pamidronate                   Same</td></tr><tr><td rowspan=1 colspan=1>Progesterone             25 mg/dL</td><td rowspan=1 colspan=1>Progesterone                   Same</td></tr></table>

Differences compared to the chosen (FDA cleared; marketed) predicate device (k972666)

<table><tr><td colspan="1" rowspan="1">Performance</td><td colspan="1" rowspan="1">Predicate DeviceTandem-MP OstaseImmunoenzymetric Assay(k972666), commercially knownas Ostase¬Æ BAP EIA</td><td colspan="1" rowspan="1">Candidate DeviceIDS-iSYS Ostase BAP(k200475)</td></tr><tr><td colspan="1" rowspan="1">Indicationsfor Use</td><td colspan="1" rowspan="1">The Ostase¬Æ BAP EIA Assay is anin vitro device indicated for thequantitative measurement of bone-specific alkaline phosphatase(BAP), an indicator of osteoblasticactivity, in human serum. Thisdevice is intended to be used as anaid in the management ofpostmenopausal osteoporosis andPaget's disease.</td><td colspan="1" rowspan="1">The IDS-iSYS Ostase¬Æ BAPassay is an in vitro diagnosticdevice intended for thequantitative determination ofbone-specific alkaline phosphatase(BAP), an indicator of osteoblasticactivity, in human serum on theIDS system. Results are to be usedin conjunction with other clinicaland laboratory data to aid theclinician in the management ofpostmenopausal osteoporosis andPaget's disease</td></tr><tr><td colspan="1" rowspan="1">Method ofdetection(Testmethodology)</td><td colspan="1" rowspan="1">Manual</td><td colspan="1" rowspan="1">Automated</td></tr><tr><td colspan="1" rowspan="1">Kit reagentcomponents</td><td colspan="1" rowspan="1">Conjugate (1 x 14 mL)anti-BAP(mouse monoclonal IgG)with biotin in a bovine/horse proteinmatrix with 0.09% sodium azideMicroplates (1 x 96 wells)Streptavidin coated plastic wellstripsZero Calibrator (1 x 14 mL)A bovine protein matrix containingno detectable concentration of BAPand 0.09% sodium azideCalibrators (1-5) (5 x 1 mL)A bovine protein matrix containingapproximately 7, 15, 30, 60 and 90ug human BAP/L and 0.09%sodium azide</td><td colspan="1" rowspan="1">Reagent CartridgeMPM1 (1 x 2.6 mL)Magnetic particles coated withstreptavidin in a Phosphate bufferwith sodium azide as preservative(&lt;0.09%)Ab-BIOT (1 x 10.5 mL)Monoclonal anti-BAP labelledwith biotin, in buffer containinghorse serum with bovine andmouse proteins and sodium azideas a preservative (&lt;0.09%)</td></tr><tr><td></td><td>Low Control (1 x 1 mL) A bovine protein matrix containing approximately 11 ug human BAP/L and 0.09% sodium azide High Control (1 x 1 mL) A bovine protein matrix containing approximately 45 ug human BAP/L and 0.09% sodium azide Wash Concentrate (1 x 50 mL) Phosphate buffered saline containing Tween Substrate (1 x 20 mL) p-nitrophenyl phosphate in a stabilizing buffer containing preservatives</td><td>SUBS (1 x 40 mL) p-nitrophenyl phosphate in a stabilizing buffer containing preservatives Calibrators (1 each of 2 concentrations levels  2.5ml per bottle). A buffered bovine protein matrix containing human BAP with sodium azide as preservative (&lt;0.09%)</td></tr><tr><td></td><td>Quench Reagent (1 x 14ml) 1 N Sodium hydroxide</td><td></td></tr><tr><td>Range of assay Sensitivity</td><td>0.7 - 90 Œºg/L LoB N/A LoD 0.7 Œºg/L</td><td>3 - 70 Œºg/L LoB 0.3 Œºg/L LoD 0.4 Œºg/L</td></tr><tr><td>Expected values</td><td>LoQ N/A Males Mean 12.3 Œºg/L Median 11.6 ¬µg/L 95th percentile 20.1 Œºg/L Pre-Menopausal Mean 8.7 Œºg/L Median 8.5 Œºg/L</td><td>LoQ 0.5 Œºg/L Males Mean 13.7 Œºg/L Median 13 Œºg/L Range 7.9 to 23.5 Œºg/L Pre-Menopausal Mean 11.5 Œºg/L Median 11.1 ¬µg/L</td></tr><tr><td rowspan="4">Precision</td><td rowspan="4">Within Run Precision n =20 2.6% to 6.5% in the concentration range 7.4 to 79.5 Œºg/L Between Run Precision n = 20</td><td>Repeatability n =80 1.7% to 2.8% in the concentration</td></tr><tr><td>range 6.2 to 59.8 ¬µg/L</td></tr><tr><td>Within Laboratory n = 80 2% to 6.4% in the concentration</td></tr><tr><td>3.0% to 7.6% in the concentration range 6.2 to 59.8 ¬µg/L</td></tr><tr><td rowspan="9">Specificity, Interfering substances And Cross Reactivity</td><td colspan="2">range 8.4 to 81.1 ¬µg/L Interfering Substances</td></tr><tr><td></td><td>Interfering Substances</td></tr><tr><td>Bilirubin 20 mg/dL</td><td>Bilirubin -</td></tr><tr><td>conjugated No Claim</td><td>conjugated 40 mg/dL</td></tr><tr><td>Biotin No Claim</td><td>Biotin 400 ng/mL</td></tr><tr><td>Cholesterol 400 ng/dL</td><td>Cholesterol 340 mg/dL</td></tr><tr><td>Estradiol 105 mg/dL</td><td>Estradiol 400 Œºg/mL</td></tr><tr><td>Etidronate 500 mg/dL</td><td>Etidronate 90 mg/dL</td></tr><tr><td>Haemoglobin No Claim</td><td>Haemoglobin 300 mg/dL</td></tr><tr><td>HAMA No Claim</td><td>HAMA 4000 ng/mL</td></tr><tr><td>PTH 1-34 No Claim</td><td>PTH 1-34 20 Œºg/dL</td></tr><tr><td>PTH 1-84 No Claim</td><td>PTH 1-84 11.8 Œºg/dL</td></tr><tr><td>Raloxifene No Claim</td><td>Raloxifene 20 Œºg/mL</td></tr><tr><td>Red Blood Cells No Claim Rheumatoid Factor No Claim</td><td>Red Blood Cells 0.3% Rheumatoid Factor 1200 IU/mL</td></tr><tr><td>(Rf)</td><td>(Rf)</td></tr><tr><td>Risedronate No Claim Total Protein</td><td>Risedronate 50 Œºg/dL</td></tr><tr><td>14 g/dL Triglycerides 2000 mg/dL</td><td>Total Protein 12 g/dL Triglycerides 667 mg/dL</td></tr><tr><td>25-hydroxyvitamin D 80,500 IU/dL</td><td>25-hydroxyvitamin D 125 ng/mL</td></tr><tr><td colspan="2">Cross Reactivity Intestinal ALP 100U/L yields a result of 1.0 ¬µg/L Liver ALP 100 U/L yields a result of 6.2¬µg/L</td></tr><tr><td colspan="2">Placental ALP Non detectable Method Against Tandem-R Ostase (k961573) comparison n = 136 Ostase¬Æ BAP EIA =</td><td colspan="2">Placental ALP Non detectable Against Ostase¬Æ BAP EIA: n = 150</td></tr></table>

<table><tr><td>Linearity</td><td>No Claim</td><td>Observed = 0.98 x (Expected) -0.9 Œºg/L Regression coefficient R2: 1.00</td></tr></table>

# Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision was evaluated in accordance with a modified protocol based on CLSI EP-5A3, ‚ÄúEvaluation of Precision Performance of Quantitative Measurement Methods‚Äù. Ten (10) native serum samples were assayed using three reagent lots in duplicate, twice per day for 20 days $\mathrm { \Delta } n { = } 8 0$ replicates per sample) on three systems.

Results from one representative reagent lot (Lot #3):   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>MeanConc.(Œºg/L)</td><td rowspan=1 colspan=1>RepeatabilitySD (Œºg/L)</td><td rowspan=1 colspan=1>Repeatability%CV</td><td rowspan=1 colspan=2>Within LaboratorySD (Œºg/L)    %CV</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.8%</td></tr><tr><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.8%</td></tr><tr><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>11.4</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.9%</td></tr><tr><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>12.1</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>4.5%</td></tr><tr><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>18.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>4.5%</td></tr><tr><td rowspan=1 colspan=1>Sample 6</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>19.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>4.6%</td></tr><tr><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>45.1</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>Sample 8</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>52.4</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>Sample 9</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>54.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.9%</td></tr><tr><td rowspan=1 colspan=1>Sample 10</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>58.6</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.5%</td></tr></table>

Results for the combined 3 lots:   

<table><tr><td rowspan="2">Sample</td><td rowspan="2">N</td><td rowspan="2">Mean Conc. (Œºg/L)</td><td colspan="2">Repeatability</td><td colspan="2">Within Laboratory</td></tr><tr><td>SD (Œºg/L)</td><td>%CV</td><td>SD (Œºg/L)</td><td>%CV</td></tr><tr><td>Sample 1</td><td>240</td><td>6.2</td><td>0.2</td><td>2.8%</td><td>0.4</td><td>5.9%</td></tr><tr><td>Sample 2</td><td>240</td><td>8.7</td><td>0.1</td><td>1.7%</td><td>0.5</td><td>6.2%</td></tr><tr><td>Sample 3</td><td>240</td><td>11.7</td><td>0.3</td><td>2.5%</td><td>0.8</td><td>6.6%</td></tr><tr><td>Sample 4</td><td>240</td><td>12.5</td><td>0.3</td><td>2.4%</td><td>0.9</td><td>7.1%</td></tr><tr><td>Sample 5</td><td>240</td><td>18.4</td><td>0.4</td><td>2.4%</td><td>1.3</td><td>6.8%</td></tr><tr><td>Sample 6</td><td>240</td><td>20.6</td><td>0.5</td><td>2.5%</td><td>1.5</td><td>7.2%</td></tr><tr><td>Sample 7</td><td>240</td><td>45.5</td><td>1.0</td><td>2.3%</td><td>1.4</td><td>3.0%</td></tr><tr><td>Sample 8</td><td>240</td><td>53.2</td><td>1.1</td><td>2.1%</td><td>1.8</td><td>3.4%</td></tr><tr><td>Sample 9</td><td>240</td><td>54.7</td><td>0.9</td><td>1.7%</td><td>2.1</td><td>3.9%</td></tr><tr><td>Sample 10</td><td>240</td><td>59.8</td><td>1.1</td><td>1.9%</td><td>2.3</td><td>3.8%</td></tr></table>

b. Linearity/assay reportable range:

A linearity study was conducted based on CLSI EP6-A for the candidate device. A high human serum sample and a low human serum sample were used to create 11 evenly spaced dilutions by mixing the high and low sample to cover the assay measuring range as indicated below:

<table><tr><td>Sample</td><td>Dilution</td><td>Dilution Factor (%)</td></tr><tr><td>1:</td><td>Low (L)</td><td>0</td></tr><tr><td>2:</td><td>0.90L + 0.10H</td><td>10</td></tr><tr><td>3:</td><td>0.80L + 0.20H</td><td>20</td></tr><tr><td>4:</td><td>0.70L + 0.30H</td><td>30</td></tr><tr><td>5:</td><td>0.60L + 0.40H</td><td>40</td></tr><tr><td>6:</td><td>0.50L + 0.50H</td><td>50</td></tr><tr><td>7:</td><td>0.40L + 0.60H</td><td>60</td></tr><tr><td>8:</td><td>0.30L + 0.70H</td><td>70</td></tr><tr><td>9:</td><td>0.20L + 0.80H</td><td>80</td></tr><tr><td>10:</td><td>0.10L + 0.90H</td><td>90</td></tr><tr><td>11:</td><td>High (H)</td><td>100</td></tr></table>

Results:

Observed $= 0 . 9 8 \mathrm { \ : x \ }$ (Expected) $- 0 . 9 \mathrm { n g / m L }$ Regression coefficient $\mathrm { R } ^ { 2 }$ : 1.00

The IDS-iSYS Ostase¬Æ %\$3DVVD\OLQHDUUDQJHZDVGHWHUPLQHGDVWR $7 8 . 5 \mu \mathrm { g } / \mathrm { L }$ ZLWKD measuring (reportable) range of 3 to $7 0 \mu \mathrm { g / L }$ 

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Calibrator traceability and value assignment

The IDS-iSYS Ostase¬Æ BAP kit calibrators are value assigned against in house secondary standard (IRs) using an internal QC procedure. The IR‚Äôs are value assigned against the predicate device (Ostase¬Æ BAP EIA assay) using the predicate assay procedure. Therefore, the kit calibrators are traceable to the predicate device via the secondary standards.

Calibrator Value Assignment and Verification Method

For kit calibrator value assignment, the kit calibrators are tested as unknowns in a minimum of 20 assay runs on one IDS-iSYS system. The secondary standards (IRs) are assayed in each of the runs, and the values of the Kit Calibrators are assigned with direct reference to the secondary standards (IRs). The assigned kit calibrator values are then verified following the IDS QC procedure; by running the assay on three different IDS systems and analyzing IQCs of known values across the range of the assay.

# Stability

Full kit stability was performed in which the kit calibrators were tested in combination with all kit combination reagents.

The stability based on real time studies determined a shelf life of 12 months.

# d. Detection limit:

The limit of blank (LoB), limit of detection (LoD) and limit of quantitation (LoQ) were determined with guidance from CLSI EP17-A, ‚ÄúProtocols for Determination of Limits of Detection and Limits of Quantitation‚Äù in three (3) kit lots.

Each LoB sample was measured in duplicate, for a total of five assays in a five-day period, generating a total of 60 replicates per kit lot. Each kit lot was tested on a different instrument. Analyse-It software was used to calculate the LoB.

The LoD was determined using ten (10) samples with very low BAP concentrations. Each LoD sample was measured in duplicate, for a total of five assays in a five-day period per kit lot. Each kit lot was tested on a different instrument. Analyse-It software was used to calculate the LoD.

The LoQ was calculated using ten (10) samples with low BAP concentration. Each LoQ sample was measured in duplicate, for a total of five assays in a five-day period. Each kit lot was tested on a different instrument. Analyse-It software was used to calculate the predicted LoQ. The claim limit for each kit lot is the actual closest value to the AnalyseIt‚Äôs precited value.

The limit of blank (LoB), limit of detection (LoD) and limit of quantitation (LoQ) were determined with guidance from CLSI EP17-A, ‚ÄúProtocols for Determination of Limits of Detection and Limits of Quantitation‚Äù using 60 replicates of blank and 10 low level samples.

<table><tr><td>Sensitivity</td><td>BAP Concentration (Œºg/L)</td></tr><tr><td>LoB (Limit of Blank)</td><td>0.3</td></tr><tr><td>LoD (Limit of Detection)</td><td>0.4</td></tr><tr><td>LoQ (Limit of Quantitation)</td><td>0.5</td></tr></table>

e. Analytical specificity:

Interference and cross-reactivity studies were performed in accordance with the CLSI EP07-A3 Interference.

To determine potential interference, two serum samples at two different concentrations of BAP were spiked with the potential interferent. Control samples (blank) were spiked with a volume of Phosphate Buffer saline (PBS) $\mathrm { ( 0 \ n g / m L ) }$ or relevant diluent equal to that of the spiked interferent. The mean of 26 replicate assays, for both spiked and control samples, were then compared. The differences observed between the mean spiked and control sample values were examined and assessed according to acceptance criteria.

For Rheumatoid factor (Rf) or total cholesterol, the interference was tested by recovery of BAP from a high serum pool spiked into a serum sample with known Rf levels or cholesterol levels. $\%$ Interference was calculated using below formula:

$\%$ Interference $=$ (mean spiked concentration ‚Äì mean un-spiked concentration) $\textbf { x } 1 0 0$

mean un-spiked concentration $\%$ Recovery was calculated using the formula below:

Recovery value $=$ Observed mean spiked value ‚Äì Observed mean unspiked value $\%$ Recovery $=$ (Recovery value / Expected Recovery value (Analyte added)) $\textbf { x } 1 0 0$

The following compounds were tested and found not to interfere significantly with the test, based on the predefined acceptance criteria of non-significant interference of $< 1 0 \%$ bias between the test and control samples:

<table><tr><td>Potential Interfering Substance</td><td>Highest concentration tested that demonstrated no significant interference</td></tr><tr><td>Acetaminophen</td><td>20 mg/dL</td></tr><tr><td>Alendronate</td><td>5 mg/dL</td></tr><tr><td>Bilirubin (Conjugated)</td><td>40 mg/dL</td></tr><tr><td>Bilirubin (Unconjugated)</td><td>40 mg/dL</td></tr><tr><td>Biotin</td><td>400 ng/mL</td></tr><tr><td>Calcium Chloride</td><td>20 mg/dL</td></tr><tr><td>Cholesterol</td><td>325 mg/dL</td></tr><tr><td>Estradiol</td><td>400 Œºg/mL</td></tr><tr><td>Etidronate</td><td>90 mg/dL</td></tr><tr><td>Haemoglobin</td><td>300 mg/dL</td></tr><tr><td>HAMA</td><td>4000 ng/mL</td></tr><tr><td>Ibuprofen</td><td>40 mg/dL</td></tr><tr><td>Pamidronate</td><td>18 mg/dL</td></tr><tr><td>Progesterone</td><td>25 mg/dL</td></tr><tr><td>PTH 1-34</td><td>20 Œºg/dL</td></tr><tr><td>PTH 1-84</td><td>11.8 Œºg/dL</td></tr><tr><td>Raloxifene</td><td>20 Œºg/mL</td></tr><tr><td>Red Blood Cells</td><td>0.3%</td></tr><tr><td>Rheumatoid Factor (RF)</td><td>1200 IU/mL</td></tr><tr><td>Risedronate</td><td>50 Œºg/mL</td></tr><tr><td>Salicylic Acid (Asprin)</td><td>50 mg/dL</td></tr><tr><td>Salmon Calcitonin</td><td>112 IU/dL</td></tr><tr><td>Total Protein</td><td>12 g/dL</td></tr><tr><td>Triglycerides</td><td>667 mg/dL</td></tr><tr><td>25-hydroxyvitamin D</td><td>125 ng/mL</td></tr></table>

Cross-reactivity testing was performed on Liver, Placental and Intestinal derived ALP.

the indicated substances were spiked into serum samples and measured with the IDS-iSYS Ostase¬Æ BAP, following the CLSI EP7-A2. The percent cross-reactivity was calculated using below formula:

$\%$ cross reactivity $=$   
(Mean concentration of spiked sample ‚Äì mean concentration of un-spiked sample) $\mathbf { x l 0 0 \% }$ Spike concentration

The substances with structures similar to bone alkaline phosphatase (BAP) were spiked into serum samples and measured with the IDS Ostase¬Æ BAP, following the CLSI EP7-A2. The exogenous substances were tested at the concentration listed below and determined to have the following percent cross-reactivity:

<table><tr><td>Cross-Reactant</td><td>Spiked Concentration</td><td>% Cross Reactivity</td></tr><tr><td>Liver ALP</td><td>745 Œºg/L</td><td>0.1%</td></tr><tr><td>Placental ALP</td><td>90 U/L</td><td>0.5%</td></tr><tr><td>Intestinal ALP</td><td>500 Œºg/L</td><td>Undetectable</td></tr></table>

f. Assay cut-off: Not applicable

# 2. Comparison studies:

The IDS-iSYS Ostase¬Æ BAP assay was compared against the IDS Ostase¬Æ BAP EIA assay, following CLSI EP-9A2 ‚ÄúMethod Comparison and Bias Estimation Using Patient Samples‚Äù. A total of 150 samples, selected to represent a wide range of BAP concentrations [3.0 to $6 7 . 6 \mu \mathrm { g / L } ]$ , was assayed by each method. Passing-Bablok regression analysis was performed on the comparative data:

<table><tr><td>N</td><td>Slope</td><td>95% CI</td><td>Intercept (Œºg/L)</td><td>95% CI</td><td>Corr. Coefficient (r)</td></tr><tr><td>150</td><td>0.99</td><td>0.97 to 1.02</td><td>0.17</td><td>-0.1 to 0.5</td><td>0.99</td></tr></table>

3. Expected values/Reference range:

The BAP concentration was measured in serum samples collected from 419 apparently healthy donors from the United States using the IDS Ostase¬Æ BAP assay. The study population included 140 males (35 to 75 years of age), 140 pre-menopausal women (35 to 45 years of age) and 139 post-menopausal women (55 to 75 years of age). The observed ranges (2.5th to 97.5th percentile) were established, according to CLSI guideline C28-A3c, ‚ÄúHow to Define and Determine Reference Intervals in the Clinical Laboratory‚Äù are summarized in the below table:

<table><tr><td>Population</td><td>N</td><td>Age (years)</td><td>(Œºg/L)</td></tr><tr><td></td><td></td><td></td><td></td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>Min.-Max</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>Observed Range</td></tr><tr><td rowspan=3 colspan=1>MalesPre-menopausalPost-menopausal</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>35 to 75</td><td rowspan=1 colspan=1>13.7</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>4.1</td><td rowspan=3 colspan=1>7.9 to 23.55.9 to 20.57.9 to 34.2</td></tr><tr><td rowspan=2 colspan=1>140139</td><td rowspan=2 colspan=1>3958</td><td rowspan=1 colspan=1>35 to 45</td><td rowspan=1 colspan=1>11.5</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>55 to 75</td><td rowspan=1 colspan=1>15.7</td><td rowspan=1 colspan=1>14.3</td><td rowspan=1 colspan=1>6.7</td></tr></table>

The above ranges should be considered as guidelines only; it is recommended that each laboratory establish its own expected range based upon its own patient population.

# Conclusion:

The IDS-iSYS Ostase¬Æ BAP assay data presented and provided are complete and supports the basis for substantial equivalence to the predicate device.